病態解析研究部門 業績集

トップページ > 病態解析研究 > 業績集

病態解析研究部門メニュー

業績集

2017年

  1. Ma M, Ren Q, Fujita Y, Yang C, Dong C, Ohgi Y, Futamura T, Hashimoto K: Alterations in the amino acids in the mouse brain regions after adjunctive treatment of brexpiprazole with fluoxetine. Psychopharmacology in press.
  2. Oda Y, Fujita Y, Oishi K, Nakata Y, Takase M, Niitsu T, Kanahara N, Shirayama Y, Hashimoto K, Iyo, M: Alterations in glutamatergic signaling in the brain of dopamine supersensitivity psychosis and non-supersensitivity psychosis model rats. Psychopharmacology in press.
  3. Nishi D, Su KP, Usuda K, Chiang YJ, Guu TW, Hamazaki K, Nakaya N, Sone T, Sano Y, Tachibana Y, Ito H, Isaka K, Hashimoto K, Hamasaki T, Matsuoka YJ: Differences between Japan and Taiwan in the treatment of pregnant women with depressive symptoms by omega-3 fatty acids: an open label pilot study. Nutritional Neurosci. 2017; In press
  4. Yang C, Ren Q, Qu Y, Zhang JC, Ma M, Dong C, Hashimoto K: Mechanistic target of rapamycin-independent antidepressant effects of (R)-ketamine in a social defeat stress model. Biol. Psychiatry 2017; in press.
  5. Qu Y, Yang C, Ren Q, Ma M, Dong C, Hashimoto K: Regional differences in dendritic spine density confer resilience to chronic social defeat stress. Acta. Neuropsychiatr.In press.
  6. Zhang JC, Yao W, Qu Y, Nakamura M, Dong C, Yang C, Ren Q, Ma M, Han M, Shirayama Y, Hayashi-Takagi A, Hashimoto K: Increased EphA4-ephexin1 signaling in the medial prefrontal cortex plays a role in depression-like phenotype.Sci. Rept. 2017; In press
  7. Han M, Zhang JC, Huang XF, Hashimoto K: Intake of 7,8-dihydroxyflavone from pregnancy to weaning prevents cognitive deficits in adult offspring after maternal immune activation. Eur. Arch. Psychiatry Clin. Neurosci. 2017 August; 267 (5): 479-483.
  8. Hashimoto K: Abnormalities in the brain-immune system in psychotic disorders: From pathogenesis to prevention. Eur. Arch. Psychaitry Clin. Neurosci. 2017 August; 267 (5): 365-367.
  9. Hashimoto K, Ishima T, Sato Y, Bruno D, Nierenberg J, Marmar CR, Zetterberg H, Blonnow K, Pomara N: Increased levels of ascorbic acid in the cerebrospinal fluid of cognitively intact elderly patients with major depression: a preliminary study. Sci. Rep. 2017 June 14; 7 (1): 3485.
  10. Xie ZM, Wang XM, Xu N, Wang J, Pan W, Tang ZQ, Hashimoto K, Yang JJ: Alterations in the inflammatory cytokines and brain-derived neurotrophic factor contribute to depression-like phenotype after spared nerve injury: improvement by ketamine. Sci. Rep. 2017 June 9; 7(1): 3124.
  11. Zhang JC, Yao W, Dong C, Yang C, Ren Q, Ma M, Hashimoto K: Blockade of interleukin-6 receptor in the periphery promotes rapid and sustained antidepressant actions: a possible role of gut-microbiota-brain axis. Transl. Psychiatry2017 May 30; 7: e1138.
  12. Nagai T, Kirihara K, Tada M, Koshiyama D, Koike S, Suga M, Araki T, Hashimoto K, Kasai K: Reduced mismatch negativity is associated with increased plasma level of glutamate in first-episode psychosis. Sci. Rep. 2017 May 23; 7: 2258.
  13. Yang B, Ren Q, Zhang JC, Chen QX, Hashimoto K: Altered expression of BDNF, BDNF pro-peptide, and their precursor proBDNF in the brain and liver tissues from psychiatric disorders: rethinking the brain-liver axis. Transl. Psychiatry 2017 May 16; 7: e1128.
  14. Yang C, Qu Y, Abe M, Nozawa D, Chaki S, Hashimoto K: (R)-ketamine shows greater potency and longer lasting antidepressant effects than its metabolite (2R,6R)-hydroxynorketamine. Biol. Psychiatry 2017; in press.
  15. Schmitt A, Martins-de-Souza D, Akbarian S, Cassoli JS, Ehrenreich H, Fischer A, Fonteh A, Gattaz WF, Gawlik M, Gerlach M, Grünblatt E, Halene T, Hasan A, Hashimoto K, Kim YK, Kirchner SK, Kornhuber J, Kraus T, Malchow B, Nascimento JM, Rossner M, Schwarz M, Steiner J, Talib I, Thibaut F, Riederer P, Falkai P, and members of the WFSBP-Task Force on Biological Markers. Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia part III: Molecular mechanisms. World J. Biol. Psychiatry 2017 August; 18 (5): 330-356.
  16. Dong C, Zhang JC, Yao W, Ren Q, Ma M, Yang C, Chaki S, Hashimoto K: Rapid and sustained antidepressant actions of mGlu2/3 receptor antagonist MGS0039 in social defeat stress model: Comparison with ketamine. Int. J. Neuropsychopharmacol. 2017 March 1; 20(3): 228-236.
  17. Akyol BS, Albayrak Y, Aksoy N, Sahin B, Beyazyuz M, Kuloglu M, Hashimoto K: Increased serum G72 protein levels in patients with schizophrenia: a potential candidate biomarker. Acta. Neuropsychiat. 2017 April; 29(2): 80-86.
  18. Yang C, Fujita Y, Ren Q, Ma M, Dong C, Hashimoto K: Bifidobacterium in the gut microbiota confer resilience to chronic social defeat stress in mice. Sci. Rep. 2017 April 3; 7: 45942.
  19. Bruno D, Nierenberg J, Cooper T, Marmar C, Zetterberg H, Blennow K, Hashimoto K, Pomara N: The recency ratio is associated with reduced CSF glutamate in late-life depression. Neurobiol. Learing Memory 2017 May; 141: 14-18.
  20. Albayrak Y, Hashimoto K: Sigma-1 receptor agonists and their clinical implications in neuropsychiatric disorders. Adv. Exp. Med. Biol. 2017; 964:153-161.
  21. Fukumoto K, Toki H, Iijima M, Hashihayata T, Yamaguchi J, Hashimoto K, Chaki S: Antidepressant potential of (R)-ketamine in rodent models: Comparison with (S)-ketamine.J. Pharmacol. Exp. Ther.2017 April; 361(1): 9-16.
  22. Shirayama Y, Hashimoto K: Effects of a single bilateral infusion of R-ketamine in the rat brain regions of a learned helplessness model of depression. Eur. Arch. Psychiatry Clin. Neurosci. 2017 March; 267(2): 177-182.
  23. Hashimoto K, Kakiuchi T, Ohba H, Nishiyama S, Tsukada H: Reduction of dopamine D2/3 receptor binding in the striatum after a single administration of esketamine, but not R-ketamine: A PET study in conscious monkeys.Eur. Arch. Psychiatry Clin. Neurosci. 2017 March; 267(2): 173-176.
  24. Matsumoto J, Hirano Y, Hashimoto K, Ishima T, Kanahara N, Shiina A, Hashimoto T, Yokote K, Murano S, Kimura H, Hosoda Y, Shimizu E, Iyo M, Nakazato M: Altered serum level of matrix metalloproteinase-9 and its association with decision-making in eating disorders. Psychiatry Clin. Neurosci. 2017 February; 71(2):124-134.
  25. Tadokoro S, Nonomura N, Kanahara N, Hashimoto K, Iyo M: Reduction of severity of recurrent psychotic episode by sustained treatment with aripiprazole in a schizophrenic patient with dopamine supersensitivity: a case report. Clin. Psychopharmacol. Neurosci. 2017 February; 15(1):76-78.
  26. Han M, Zhang JC, Hashimoto K: Increased levels of C1q in the prefrontal cortex of adult offspring after maternal immune activation: Prevention by 7,8-dihydroxyflavone. Clin. Psychopharmacol. Neurosci. 2017 February; 15(1): 64-67.
  27. Ma M, Ren Q, Yang C, Zhang JC, Yao, W, Dong C, Ohgi Y, Futamura T, Hashimoto K: Antidepressant effects of combination of brexpiprazole and fluoxetine on depression-like behavior and dendritic changes in mice after inflammation. Psychopharmacology 2017 February; 234 (4): 525-533.
  28. Zhang JC, Yao W, Dong C, Yang C, Ren Q, Ma M, Han M, Wu J, Ushida Y, Suganuma H, Hashimoto K: Prophylactic effects of sulforaphane on depression-like behavior and dendritic changes in mice after inflammation. J. Nutri. Biochem. 2017 January; 39: 134-144.
  29. 橋本謙二:即効性抗うつ薬ケタミンの最新トピックス.日本神経精神薬理学雑誌 2017年6月; 37(3): 71-78.
  30. 佐々木剛、橋本謙二、伊豫雅臣:思春期の心的外傷後ストレス障害(PTSD)患者を対象としたイフェンプロジル酒石酸塩の有効性を検討するためのプラセボ対照二重盲検比較試験.日本生物学的精神医学会誌 2017年6月;28 (2): 95-99.

2016年

  1. Yang B, Ren Q, Ma M, Chen QX, Hashimoto K: Antidepressant effects of (+)-MK-801 and (-)-MK-801 in the social defeat stress model. Int. J. Neuropsychopharmacol. 2016 December 30; 19(12): pyw080.
  2. Ma M, Ren Q, Yang C, Zhang JC, Yao W, Dong C, Ohgi Y, Futamura T, Hashimoto K: Adjunctive treatment of brexpiprazole with fluoxetine shows a rapid antidepressant effect in a social defeat stress model: role of BDNF-TrkB signaling. Scientific Rep. 2016 December 19; 6: 39209.
  3. Yuan K, Han Y, Hashimoto K, Lu L: On the eve of upgrading antidepressants: (R)-ketamine and its metabolites. Neurosci. Bull.2016 December; 32(6): 565-568.
  4. Zhu W, Ding Z, Zhang Y, Shi J, Hashimoto K, Lu L: Risks associated with the misuse of ketamine as a rapid-acting antidepressant. Neurosci. Bull. 2016 December; 32(6): 557-564.
  5. Yao W, Zhang JC, Ishima T, Ren Q, Yang C, Dong C, Ma M, Saito A, Honda T, Hashimoto K: Antidepressant effects of TBE-31 and MCE-1, the novel Nrf2 activators, in inflammation model of depression. Eur. J. Pharmacol. 2016; December; 793: 21-27.
  6. Fujita Y, Ishima T, Hashimoto K: Supplementation with D-serine prevents the onset of cognitive deficits in adult offspring after maternal immune activation. Scientific Rep. 2016 November 17 ;6:37261.
  7. Zhang JC, Yao W, Ren Q, Yang C, Dong C, Ma M, Wu J, Hashimoto K: Depression-like phenotype by deletion of α7 nicotinic acetylcholine receptor: Role of BDNF-TrkB signaling in nucleus accumbens. Scientific Rep. 2016 November 8; 6: 36705
  8. Hashimoto K: Ketamine’s antidepressant action: beyond NMDA receptor inhibition. Expert Opin. Ther. Targets. 2016 November; 20(11): 1389-1392.
  9. Han M, Zhang JC, Yao W, Yang C, Ishima T, Re Q, Ma M, Dong C, Huang XF, Hashimoto K: Intake of 7,8-dihydroxyflavone during juvenile and adolescent stages prevents onset of psychosis at adult offspring after maternal immune activation. Scientific Rep. 2016 November 8; 6: 36087.
  10. Ishizu N, Yui D, Hebisawa A, Aizawa H, Cui W, Fujita Y, Hashimoto K, Ajioka I, Mizusawa H, Yokota T, Watase K: Impaired striatal dopamine release in homozygous Vps35 D620N knock-in mice. Hum. Mol. Genet. 2016 October; 25(20): 4507-4517.
  11. Nishimura Y, Kawakubo Y, Suga M, Hashimoto K, Takei Y, Takei K, Inoue H, Yumoto M, Takizawa R, Kasai K: Familial influences on mismatch negativity and its association with plasma glutamate level: A magnetoencephalography study in twins. Mol. Neuropsychiatry 2016 October; 2(3): 161-172.
  12. Hashimoto K: Soluble epoxide hydrolase: a new therapeutic target for depression. Expert Opin. Ther. Targets 2016 October; 20 (10): 1149-1151.
  13. Yang B, Zhang JC, Han M., Yao W, Yang C, Ren Q, Ma M, Chen QX, Hashimoto K: Comparison of R-ketamine and rapastinel antidepressant effects in the social defeat stress model of depression. Psychopharmacology 2016 October; 233 (19): 3647-3657.
  14. Nishi D, Su KP, Usuda K, Chiang YJ, Guu TW, Hamazaki K, Nakaya N, Sone T, Sano Y, Tachibana Y, Ito H, Isaka K, Hashimoto K, Hamasaki T, Matsuoka YJ: (2016) The synchronized trial on expectant mothers with depressive symptoms by omega-3 PUFAs (SYNCHRO): Study protocol for a randomized controlled trial. BMC Psychiatry 2016 September 15; 16(1): 321.
  15. Sasaki T, Hashimoto K, Oda K, Ishima T, Yakita M, Kurata T, Kunou M, Takahashi J, Kamata Y, Kimura A, Niitsu T, Komatsu H, Hasegawa T, Shiina A, Hashimoto T, Kanahara N, Shimizu E, Iyo M: Increased serum levels of oxytocin in 'treatment of resistant depression in adolescents (TORDIA)' group. PLoS One August 17; 11(8): e0160767.
  16. Hashimoto K: Detrimental side effects of repeated ketamine infusions in the brain. Am. J. Psychiatry 2016 October; 173(10):1044-1045.
  17. Schmitt A, Rujescu D, Gawlik M, Hasan A, Hashimoto K, Iceta S, Jarema M, Kambeitz J, Kasper S, Keeser D, Kornhuber J, Koutsouleris N, Lanzenberger R, Malchow B, Saoud M, Spies M, Stöber G, Thibaut F, Riederer P, Falkai P; WFSBP Task Force on Biological Markers. Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia part II: Cognition, neuroimaging and genetics. World J. Biol. Psychiatry 2016 September; 17 (6): 406-428.
  18. Yao W, Zhang JC, Ishima T, Dong C, Yang C, Ren Q, Ma M, Han M, Wu J, Suganuma H, Ushida Y, Yamamoto M, Hashimoto K: Role of Keap1-Nrf2 in depression and dietary intake of glucoraphanin confers stress resilience in mice. Scientific Reports 2016 July 29; 6: 30659
  19. Hashimoto K: R-ketamine: a rapid-onset and sustained antidepressant without risk of brain toxicity. Psychol. Med. 2016 August; 46 (11): 2449-2451.
  20. Zhong N, Jiang H, Du J, Zhao Y, Sun H, Xu D, Li C, Zhuang W, Li X, Hashimoto K, Zhao M: The cognitive impairments and psychological wellbeing of methamphetamine dependent patients compared with healthy controls. Prog. Neuropsychopharmacol. Biol. Psychiatry 2016 August; 69: 31-37.
  21. Yang B, Yang C, Ren Q, Zhang JC, Chen QX, Shirayama Y, Hashimoto K: Regional differences in the expression of brain-derived neurotrophic factor (BDNF) pro-peptide, its precursors preproBDNF and proBDNF in the brain confer stress resilience. Eur. Arch. Psychiatry Clin. Neurosci. 2016 December; 266(6): 765-769.
  22. Beyazyuz M, Küfeciler T, Bulut L, Ünsal C, Albayrak Y, Baykal S, Kuloglu M, Hashimoto K: Increased serum levels of apoptosis in deficit-syndrome schizophrenia patients: A preliminary study. Neuropsychaitric. Dis. Treatment 2016 May 23; 12: 1261-1268.
  23. Nishi D, Su KP, Usuda K, Chiang YJ, Guu TW, Hamazaki K, Nakaya N, Sone T, Sano Y, Ito H, Isaka K, Hashimoto K, Hamasaki T, Matsuoka YJ: Omega-3 fatty acid supplementation for expectant mothers with depressive symptoms in Japan and Taiwan: an open-label trial. Psychiatry Clin. Neurosci. 2016 June;70(6): 253-254.
  24. Yoshimi N, Futamura T, Kakumoto K, Salehi AM, Sellgren C, Holmén-Larsson J, Jakobsson J, Pålsson E, Landén M, Hashimoto K: Blood metabolomics identifies abnormalities in the citric acid, urea cycle, and amino acid metabolim in bipolar disorder. BBA Clinical 2016 April 3; 5: 151-158.
  25. Zhang JC, Yao W, Hashimoto K: Brain-derived neurotrophic factor (BDNF) – TrkB signaling in inflammation-related depression and potential therapeutic target. Curr. Neuropharmacol. 2016 August 30; 14 (7): 721-731.
  26. Ren Q, Ma M, Hashimoto K: Current status of substance abuse in East Asia and its therapeutic prospects. East Asian Arch. Psychiatry 2016 June 30; 26: 45-51.
  27. Yoshimi N, Futamura T, Bergen SE, Iwayama Y, Ishima T, Sellgren C, Ekman CJ, Jakobsson J, Pålsson E, Kakumoto K, Ohgi Y, Yoshikawa T, Landén M, Hashimoto K: Cerebrospinal fluid metabolomics identifies a key role of isocitrate dehydrogenase in bipolar disorder: Evidence in support of mitochondrial dysfunction hypothesis. Mol. Psychiatry 2016 November; 21(11):1504-1510.
  28. Hashimoto K, Yoshida T, Ishikawa M, Fujita Y, Niitsu T, Nakazato M, Watanabe H, Sasaki T, Shiina A, Hashimoto T, Kanahara N, Hasegawa T, Enohara M, Kimura A, Iyo M: Increased serum levels of serine enantiomers in patients with depression. Acta. Neuropsychiatr. 2016 June; 28 (3): 173-178.
  29. Ren Q, Ma M, Ishima T, Morisseau C, Yang J, Wagner K, Zhang JC, Yang C, Yao W, Dong C, Han M, Hammock BD, Hashimoto K: Gene deficiency and pharmacological inhibition of soluble epoxide hydrolase confers resilience to repeated social defeat stress. Proc. Natl. Acad. Sci. USA 2016 March 29; 113(13): E1944-52.
  30. Yang C, Han M, Zhang JC, Ren Q, Hashimoto K: Loss of parvalbumin-immunoreactivity in mouse brain regions after repeated intermittent administration of esketamine, but not R-ketamine. Psychiatry Res. 2016 March 24; 239: 281-283.
  31. Kamada Y, Hashimoto R, Yamamori H, Yasuda Y, Takehara T, Fujita Y, Hashimoto K, Miyoshi E: Impact of plasma transaminase levels on the peripheral blood glutamate levels and memory functions in healthy subjects. BBA Clinical 2016 February 23; 5: 101-107.
  32. Hashimoto K: Ethnic differences in the serum levels of proBDNF, a precursor of brain-derived neurotrophic factor (BDNF) in mood disorders. Eur. Arch. Psychiatry Clin. Neurosci. 2016 April; 266 (3): 285-287.
  33. Hashimoto K: Regulation of brain-derived neurotrophic factor (BDNF) and its precursor proBDNF in the brain by serotonin. Eur. Arch. Psychiatry Clin. Neurosci. 2016 April; 266(3): 195-197.
  34. Niimi M, Hashimoto K, Kakuda W, Miyano S, Momosaki R, Ishima T, Abo M: Role of brain-derived neurotrophic factor in beneficial effects of repetitive transcraniual magnetic stimulation for upper limb hemiparesis after stroke. PLoS One 2016 March 23; 11(3): e0152241.
  35. Hashimoto K, Bruno D, Nierenberg J, Marmar CR, Zetterberg H, Blonnow K, Pomara N: Abnormality in glutamine-glutamate cycle in the cerebrospinal fluid of cognitively intact elderly individuals with major depressive disorder: 3-year follow-up study. Transl. Psychiatry 2016 March 1; 6: e744.
  36. Dong C, Zhang JC, Yao W, Ren Q, Yang C, Ma M, Han M, Saito R, Hashimoto K: Effects of escitalopram, R-citalopram, and reboxetine on serum levels of tumor necrosis factor-α, interleukin-10, and depression-like behavior in mice after lipopolysaccharide administration. Pharmacol. Biochem. Behav. 2016 February 15; 144: 7-12.
  37. Sun HL, Zhou ZQ, Zhang GF, Yang C, Wang XM, Shen JC, Hashimoto K, Yang JJ: Hippocampal p11 plays a role in the sustained antidepressant effect of ketamine in the chronic unpredictable mild stress model. Transl. Psychiatry 2016 February 23; 6: e741.
  38. Nishinaka H, Nakane J, Nagata T, Imai A, Kuroki N, Sakikawa N, Omori M, Kuroda O, Hirabayashi N, Igarashi Y, Hashimoto K: Neuropsychological impairment and its association with violence risk in Japanese forensic psychiatric patients: a case-control study. PLoS One 2016 Jan 29; 11(1): e0148354.
  39. Hashimoto K: Serine enantiomers as diagnostic biomarkers for schizophrenia and bipolar disorder. Eur. Arch. Psychiatry Clin. Neurosci. 2016 February; 266 (1): 83-85.
  40. Liu WX, Wang J, Xu N, Xie ZM, Zhang GF, Jia M, Zhou ZQ, Hashimoto K, Yang, JJ: Regulation of glutamate transporter via BDNF-TrkB signaling plays a role in the anti-apoptotic and antidepressant effects of ketamine in chronic unpredictable stress model of depression. Psychopharmacology 2016 February; 233 (3): 405-415.
  41. Shirayama Y, Takahashi M, Suzuki M, Sato K, Hashimoto K: Effects of add-on tipepidine on treatment-resistant depression: an open-label pilot trial. Acta. Neuropsychiatr. 2016 February; 28(1): 51-54.
  42. Yamamori H, Ishima T, Yasuda Y, Fujimoto M, Kudo N, Ohi K, Hashimoto K, Takeda M, Hashimoto R: Assessment of a multi-assay biological diagnostic test for mood disorders in a Japanese population. Neurosci. Lett. 2016 January 26; 612, 167-171.
  43. 橋本謙二:ブロッコリースプラウトを用いた精神疾患の発症予防の可能性.日本生物学的精神医学会誌 2016年12月号;27(4):188-191
  44. 橋本謙二(2016)気分障害の血液バイオマーカーとしてのBDNFおよびproBDNF.生体の科学 2016年9-10月号;67(5): 480-481
  45. 橋本謙二:クエン酸回路のイソクエン酸脱水素酵素.分子精神医学 2016年7月号;16(3):51-53.
  46. 橋本謙二: 新規抗うつ薬としてのグルタミン酸神経系薬剤.臨床精神薬理 2016年7月号;19(7):943-949.
  47. 橋本謙二:うつ病治療におけるBDNF-TrkB-mTORシグナルの役割.日本生物学的精神医学会誌 2016年3月号;27 (1): 22-26.

2015年

  1. Shirayama Y, Yang C, Zhang JC, Ren Q, Yao W, Hashimoto K: Alterations in brain-derived neurotrophic factor (BDNF) and its precursor proBDNF in the brain regions of a learned helplessness rat model and antidepressant effects of TrkB agonist and antagonist. Eur. Neuropsychopharmacol. 2015 Dec; 25 (12): 2449-2458
  2. Dong C, Hashimoto K: Early intervention for psychosis with NMDAR modulators. Clin. Psychopharmacol. Neurosci. 2015 Dec 31; 13(3): 328-329.
  3. Ageta-Ishihara N, Yamazaki M, Konno K, Nakayama H, Abe M, Hashimoto K, Nishioka T, Kaibuchi K, Miyakawa T, Hashimoto K, Watanabe M, Sakimura K, Kinoshita M: CDC42EP4-septin complex in perisynaptic domains of Bergmann glia facilitates cerebellar motor learning via GLAST-mediated glutamate clearance from the parallel fiber-Purkinje cell synapses. Nature Comm. 2015 Dec 10; 6: 10090.
  4. Zhang JC, Yao W, Dong C, Yang C, Ren Q, Ma M, Han M, Hashimoto K: Comparison of ketamine, 7,8-dihydroxyflavone and ANA-12 antidepressant effects in the social defeat stress model of depression. Psychopharmacology 2015 Dec; 232(23): 4325-4335.
  5. Nishi D, Hashimoto K, Noguchi H, Hamazaki K, Hamazaki T, Matsuoka Y: Glutamatergic system abnormalities in posttraumatic stress disorder. Psychopharmacology 2015 Dec; 232(23): 4261-4268.
  6. Nakazato M, Sutoh C, Matsuzawa D, Ishima T, Hirano Y, Hashimoto T, Niitsu T, Kanahara N, Shiina A, Tadokoro S, Abe T, Asano K, Ishikawa M, Shiraishi T, Kobori O, Shimizu E, Iyo M, Hashimoto K: Decreased serum levels of glutamate in women with anorexia nervosa and bulimia nervosa. Open Nutrition J. 2015; 9: 5-11.
  7. Oda Y, Tadokoro S, Takase M, Kanahara N, Watanabe H, Shirayama Y, Hashimoto K, Iyo M: G protein-coupled receptor kinase 6/β-arrestin 2 system in a rat model of dopamine supersensitivity psychosis. J. Psychopharmacol. 2015 Dec; 29(12): 1308-1313.[Pubmed]
  8. Ren Q, Ma M, Yang C, Zhang JC, Yao W, Hashimoto K: BDNF-TrkB signaling in the nucleus accumbens shell of mice plays a role in methamphetamine withdrawal symptoms. Transl. Psychiatry 2015 October 27; 5: e666.
  9. Yang C, Shirayama Y, Zhang JC, Ren Q, Yao W, Ma M, Dong C, Hashimoto K: R-Ketamine: A rapid onset and sustained antidepressant without psychotomimetic side effects. Transl. Psychiatry 2015 September 1; 5: e632.
  10. Sasaki T, Hashimoto K, Oda Y, Ishima T, Kurata T, Takahashi T, Kamata Y, Kimura H, Niitsu T, Komatsu H, Ishikawa M, Hasegawa T, Shiina A, Hashimoto T, Kanahara N, Shiraishi T, Iyo M: Decreased levels of serum oxytocin in pediatric patients with attention deficit/hyperactivity disorder. Psychiatry Res.2015 August 30; 228(3): 746-751.[Pubmed]
  11. Oda Y, Kanahara N, Kimura H, Watanabe H, Hashimoto K, Iyo M: Genetic association between G protein-coupled receptor kinase 6/β-arrestin 2 and dopamine supersensitivity psychosis in schizophrenia. Neuropsychaitric Dis. Treatment 2015 July 29; 11: 1845-1854.[Pubmed]
  12. Matsuoka Y, Nishi D, Hamazaki K, Yonemoto N, Matsumura K, Noguchi H, Hashimoto K, Hamazaki T: Docosahexaenoic acid for selective prevention of posttraumatic stress disorder among severity injured patients: A randomized, placebo-controlled trial. J. Clin. Psychiatry 2015 August 26; 76 (8): e1015-e1022.
  13. Shirayama Y, Ishima T, Oda Y, Okamura N, Iyo M, Hashimoto K: Opposite roles for neuropeptide S in the nucleus accumbens and bed nucleus of the stria terminals in learned helplessness rats. Behav. Brain Res. 2015 September 15; 291: 67-71.[Pubmed]
  14. Hashimoto K: Role of EphA4 signaling in the pathogenesis of amyotrophic lateral sclerosis and therapeutic potential of traditional Chinese medicine rhynchophylline. Psychopharmacology 2015 August; 232 (15): 2873-2875.[Pubmed]
  15. Hashimoto K: Minocycline and St. John’s wort as therapeutic drugs for human tauopathy. Biol. Psychiatry 2015 November 15; 78 (10): e39.
  16. Yao W, Zhang JC, Chao D, Zhuang C, Hirota S, Inanaga K, Hashimoto K: Effects of amycenone on serum levels of tumor necrosis factor-α and depression-like behaviors in mice after administration of lipopolysaccharide. Pharmacol. Biochem. Behav.2015 September; 136: 7-12.[Pubmed]
  17. Yang C, Hashimoto K: Peripheral IL-6 signaling: a promising therapeutic target for depression? Expert Opin. Investig. Drugs 2015; 24 (7): 1-2.[Pubmed]
  18. Nishi D, Hashimoto K, Noguchi H, Kim Y, Matsuoka Y: Serum oxytocin, posttraumatic coping and C-reactive protein in motor vehicle accident survivors by gender. Neuropsychobiol.2015 June; 71(4): 196-201.[Pubmed]
  19. Yang C, Shirayama Y, Zhang JC, Ren Q, Hashimoto K: Peripheral interleukin-6 promotes resilience versus susceptibility to inescapable stress. Acta. Neuropsychiatr. 2015 October; 27 (05): 312-326.[Pubmed]
  20. Shirai Y, Fujita Y, Hashimoto R, Ohi K, Yamamori H, Yasuda Y, Ishima T, Suganuma H, Ushida Y, Takeda M, Hashimoto K: Dietary intake of sulforaphane during juvenile and adolescence can prevent phencyclidine-induced cognitive deficits at adulthood. PLoS One 2015 June 24; 10 (6): e0127244.
  21. Yang C, Ren Q, Zhang JC, Hashimoto K: Tropisetron for postoperative cognitive decline. Aust. N.Z. Psychiatry2015 July; 49 (7): 662-663. [Pubmed]
  22. Ohgi Y, Futamura T, Hashimoto K: Glutamate signaling in the synaptogenesis for psychiatric disorders and NMDA receptor as a potential therapeutic target. Curr. Mol. Med. 2015 May 5; 15 (3): 206-221. [Pubmed]
  23. Hashimoto K: Targeting of α7 nicotinic acetylcholine receptor in the treatment of schizophrenia and the use of auditory sensory gating as a translational biomarker. Curr. Pham. Des. 2015; 21 (26): 3797-3806 [Pubmed]
  24. Hashimoto K: Inflammatory biomarkers as differential predictors for antidepressant response. Int. J. Mol. Sci. 2015 April 8; 16: 7796-7801. [Pubmed]
  25. Ishima T, Futamura T, Ohgi Y, Yoshimi N, Kikuchi T, Hashimoto K: Potentiation of neurite outgrowth by brexpiprazole, a novel serotonin-dopamine activity modulator: a role for serotonin 5-HT1A and 5-HT2A receptors. Eur. Neuropsychopharmacol. 2015 April 18; 25 (4): 505-511 [Pubmed]
  26. Hashimoto K: Targeting the sigma-1 receptor chaperone in the treatment of perinatal brain injury. Exp. Neurol. 2015 January 31; 265: 118-121. [Pubmed]
  27. Yang C, Shirayama Y, Zhang JC, Ren Q, Hashimoto K: Regional differences in brain-derived neurotrophic factor and dendtritic spine density confer resilience to inescapable stress. Int. J. Neuropsychopharmacol.2015 May 01; 18(7): pyu121.
  28. Akyol ES, Albayrak Y, Beyazyüz M, Aksoy N, Kuloglu M, Hashimoto K: Decreased serum levels of brain-derived neurotrophic factor in schizophrenic patients with deficit syndrome. Neuropsychiatr. Dis. Treatment 2015; 11: 865-872. [Pubmed]
  29. Yoshimi N, Futamura T, Hashimoto K: Improvement of dizocilpine-induced social recognition deficits in mice by brexpiprazole, a novel serotonin-dopamine activity nodulator. Eur. Neuropsychopharmacol. 2015 March; 25: 356-364 [Pubmed]
  30. Matsuura A, Fujita Y, Iyo M, Hashimoto K: Effects of sodium benzoate on prepulse inhibition deficits and hyperlocomotion in mice after administration of phencyclidine. Acta. Neuropsychiatr. 2015 June; 27 (3): 159-167.[Pubmed]
  31. Levin R, Abarbanel A, Edelman S, Durrant AR, Hashimoto K, Javitt DC, Heresco-Levy U: Behavioral and cognitive effects of the N-methyl-D-aspartate receptor co-agonist D-serine in healthy humans. J. Psychiatry Res. 2015 February; 61: 188-195. [Pubmed]
  32. Hashimoto K: Activation of sigma-1 receptor chaperone in the treatment of neuropsychiatric diseases and its clinical implication. J. Pharmacol. Sci. 2015; January; 127 (1): 6-9. [Pubmed]
  33. Hashimoto K: Brain-derived neurotrophic factor (BDNF) and its precursor proBDNF as a diagnosic biomarker for major depression and bipolar depression. Eur. Arch. Psychiatry Clin. Neurosci. 2015 February; 265 (1): 83-84. [Pubmed]
  34. Guo TY, Liu LJ, Xu LZ, Zhang JC, Li SX, Chen C, He LG, Chen YM, Yang HD, Lu Li, Hashimoto K: Alterations of the daily rhythms of HPT axis induced by chronic unpredicted mild stress in rats. Endocrine 2015 March; 48: 637-643. [Pubmed]
  35. Hashimoto K, Sasaki T: Old drug tipepidine as new hope for children with ADHD. Austr. N. Z. J. Psychiatry 2015 February; 49(2): 181-184. [Pubmed]
  36. Yang C, Hashimoto K: Combination of nitrous oxide with isoflurane or scopolamine for treatment-resistant major depression. Clin. Psychopharmacol. Neurosci. 2015 April; 13 (1): 118-120. [Pubmed]
  37. Shiina A, Kanahara N, Sasaki T, Tsuru K, Hashimoto T, Hasegawa T, Yoshida T, Iyo M, Hashimoto K: An open study of sulforaphane-rich broccoli sprout extract in patients with schizophrenia. Clin. Psychopharmacol. Neurosci. 2015 April; 13 (1): 62-67. [Pubmed]
  38. Zhang JC, Wu J, Fujita Y, Yao W, Ren Q, Yang C, Li SX, Shirayama Y, Hashimoto K: Antidepressant effects of TrkB ligands on depression-like behavior and dendritic changes in the hippocampus and nucleus accumbens after inflammation. Int. J. Neuropsychopharmacol. 2015 April 01; 18 (4): pyu077. [Pubmed]
  39. Matsuzawa D, Shirayama Y, Niitsu T, Hashimoto K, Iyo M: Deficits in emotion based decision-making in schizophrenia: a new insight based on the Iowa Gambling task. Prog. Neuropsychopharmacol. Biol. Psychiatry 2015 March 3; 57: 52-59. [Pubmed]
  40. Yang JJ, Wang N, Yang C, Shi JY, Yu HY, Hashimoto K: Serum interleukin-6 is a predictive biomarker for ketamine’s antidepressant effect in treatment-resistant patients with major depression. Biol. Psychiatry 2015 February 1; 77 (3): e19-e20. [Pubmed]
  41. Pålsson E, Jakobsson J, Södersten K, Fujita Y, Sellgren C, Ekman CJ, Ågren H, Hashimoto K, Landén M: Markers of glutamate signaling in cerebrospinal fluid and serum from patients with bipolar disorder and healthy controls. Eur. Neuropsychopharmacol. 2015 January; 25 (1): 133-140. [Pubmed]
  42. Hashimoto K: Tropisetron and its targets in Alzheimer’s disease. Expert Opin. Ther. Targets 2015 January; 19(1): 1-5. [Pubmed]
  43. 橋本謙二:統合失調症の認知機能障害に対する治療薬開発の現状と課題.臨床精神薬理 2015年12月;18 (12): 1543-1548.
  44. 橋本謙二:即効性抗うつ薬としてのケタミン発見.臨床精神医学 2015年7月;44(7): 979-983.
  45. 橋本謙二:うつ病治療におけるケタミンの効果と危険性:クロルプロマジンに次ぐ大発見!日本医事新報 2015年5月30日;4753:51.
  46. 橋本謙二:酸化的ストレス・炎症からみた精神疾患発症の予防の可能性.日本生物学的精神医学会誌 2015年3月; 26 (1): 34-37.

2014年

  1. Yamamori H, Hashimoto R, Fujita Y, Numata S, Yasuda Y, Fujimoto M, Ohi K, Umeda-Yano S, Ito A, Ohmori T, Hashimoto K, Takeda M: Changes in plasma D-serine, L-serine, and glycine levels in treatment-resistant schizophrenia before and after clozapine treatment. Neurosci. Lett. 2014 September 10; 582: 93-98. [Pubmed]
  2. Kishimoto A, Goto Y, Hashimoto K: Post-traumatic stress disorder symptoms in a female patient following repeated teasing: Treatment with gabapentin and lamotrigine and the possible role of sensitization. Clin. Psychopharmacol. Neurosci. 2014 December; 12(3): 240-242.[Pubmed]
  3. Hashimoto K: Brain-derived neurotrophic factor (BDNF) and its precursor proBDNF as predictable biomarkers for bipolar disorder. Bri. J. Psychiatry 2014 November; 205: 410.
  4. Chen C, Jiang W, Zhong N, Wu J, Jiang H, Du J, Li Y, Ma XC, Zhao M, Hashimoto K, Gao C: Impaired processing speed and attention in first-episode drug naive schizophrenia with deficit syndrome. Schizophrenia Res. 2014 November 15; 159: 478-484.[Pubmed]
  5. Hashimoto K: Blood D-serine levels as a predictive biomarker for the rapid antidepressant effects of the NMDA receptor antagonist ketamine. Psychopharmacology 2014 October; 231: 4081-4083. [Pubmed]
  6. Suzuki M, Takahashi M, Muneoka K, Sato K, Hashimoto K, Shirayama Y: A study of remitted and treatment-resistant depression using NMPI and including pessimism and optimis scales. PLoS One 2014 October; 9 (10): e109137.
  7. Yoshimi N, Fujita Y, Ohgi Y, Futamura T, Kikuchi T, Hashimoto K: Effects of the novel antipsychotic drug brexpiprazole on phencyclidine-induced cognitive deficits in mice: a role for serotonin 5-HT1A receptor. Pharmacol. Biochem. Behav. 2014 September; 124: 245-249. [Pubmed]
  8. Hashimoto K: Targeting of NMDA receptors in the new treatment of schizophrenia. Expert Opin. Ther. Targets 2014 September; 18 (9): 1049-1063. [Pubmed]
  9. Li SX, Zhang JC, Wu J, Hashimoto K: Antidepressant effects of ketamine on depression-like behaviors in juvenile mice after neonatal dexamethasone exposure. Clin. Psychopharmacol. Neurosci. 2014 August; 12(2):124-127. [Pubmed]
  10. Dang YH, Ma XC, Zhang JC, Ren Q, Wu J, Gao GG, Hashimoto K: Targeting of the NMDA receptors for the treatment of major depression. Curr. Pham. Des. 2014; 20 (32): 5151-5129. [Pubmed]
  11. Niitsu T, Shirayama Y, Matsuzawa D, Shimizu E, Hashimoto K, Iyo M: Association between serum levels of glial cell-line derived neurotrophic factor and attention deficits in schizophrenia. Neurosci. Lett. 2014 July 11; 575: 37-41. [Pubmed]
  12. Hashimoto K: Abnormalities of the glutamine-glutamate-GABA cycle in the schizophrenia brain. Schizophrenia Res. 2014 July; 156: 281-282. [Pubmed]
  13. Nishi D, Hashimoto K, Noguchi H, Matsuoka Y: Serum neuropeptide Y in accident survivors with depression or posttraumatic stress disorder. Neurosci. Res. 2014 June; 83:8-12. [Pubmed]
  14. Sasaki T, Hashimoto K, Tachibana M, Kurata T, Okawada K, Ishikawa M, Kimura H, Komatsu H, Ishikawa M, Hasegawa T, Shiina A, Hashimoto T, Kanahara N, Shiraishi T, Iyo M: Tipepidine in adolescent patients with depression: A 4-week, open-label, preliminary study. Neuropsychiatrc Disease Treatment 2014 May 5; 10:719-722. [Pubmed]
  15. Hashimoto K: Serum BDNF as a predictor of incident dementia. JAMA Neurol. 2014 May; 71(5):653. [Pubmed]
  16. Yang C, Hashimoto K: Rapid antidepressant effects and abuse liability of ketamine. Psychopharmacology 2014 May; 231 (9):2041-2042. [Pubmed]
  17. Kimura H, Kanahara N, Komatsu N, Ishige M, Muneoka K, Yoshimura M, Yamanaka H, Suzuki T, Komatsu H, Sasaki T, Hashimoto T, Hasegawa T, Shiina A, Ishikawa M, Sekine Y, Shiraishi T, Watanabe H, Shimizu E, Hashimoto K, Iyo M: A prospective comparative study of risperidone long-acting injectable for treatment-resistant schizophrenia with dopamine supersensitivity psychosis. Schizophrenia Res. 2014 May; 155(1-3):52-58.[Pubmed]
  18. Södersten K, Pålsson E, Beneroso KLF, Ishima T, Landén M, Funa K, Hashimoto K, Ågren H: Abnormality in serum levels of mature brain-derived neurotrophic factor (BDNF) and its precursor proBDNF in mood-stabilizing patients with bipolar disorder: A study from two independent sets. J. Affect Dis. 2014 May; 160: 1-9. [Pubmed]
  19. Hashimoto K: R-Stereoisomer of ketamine as alternative of ketamine for treatment-resistant major depression. Clin. Psychopharmacol. Neurosci. 2014 May; 12(1): 72-73. [Pubmed]
  20. Ma M, Ren Q, Zhang JC, Hashimoto K: Effects of brilliant blue G on serum levels of tumor necrosis factor-alpha and depression-like behaviors in mice after administration of lipopolysaccharide. Clin. Psychopharmacol. Neurosci. 2014 May; 12(1): 31-36. [Pubmed]
  21. Ishima T, Fujita Y, Hashimoto K: Interaction of new antidepressants with sigma-1 receptor chaperones and their potentiation of neurite outgrowth in PC12 cells. Eur. J. Pharmacol. 2014 March; 727: 167-173. [Pubmed]
  22. Niitsu T, Ishima T, Yoshida T, Hashimoto T, Matsuzawa D, Shirayama Y, Nakazato M, Shimizu E, Hashimoto K, and Iyo M: A positive correlation between serum levels of mature brain-derived neurotrophic factor and negative symptoms in schizophrenia. Psychiatry Res. 2014 February 28; 215 (2): 268-273. [Pubmed]
  23. Hashimoto K: Book Forum on “A Disability of the Soul: An Ethnography of Schizophrenia and Mental Illness in Contemporary Japan, edited by Karen Nakamura, Cornell University Press, 2013, 264 pp., $24.95 (paper). Am. J. Psychiatry 2014 February; 171 (2): 231. [Pubmed]
  24. Sasaki T, Hashimoto K, Tachibana M, Kurata T, Okawada K, Ishikawa M, Kimura H, Komatsu H, Ishikawa M, Hasegawa T, Shiina A, Hashimoto T, Kanahara N, Shiraishi T, Iyo M: Tipepidine in children with Attention-Deficit/Hyperactivity Disorder: A 4-week, open-label, preliminary study. Neuropsychiatrc. Dis. Treatment 2014 January; 10: 147-151. [Pubmed]
  25. Li SX, Fujita Y, Zhang JC, Ren Q, Ishima T, Wu J, Hashimoto K: Role of the NMDA receptor in cognitive deficits, anxiety, and depressive-like behavior in juvenile and adult mice after neonatal dexamethasone exposure. Neurobiol. Dis. 2014 February; 62: 124-134 [Pubmed]
  26. Ren Q, Zhang JC, Ma M, Fujita Y, Wu J, Hashimoto K: Protective effects of TrkB agonist 7,8-dihydroxyflavone on the behavioral changes and neurotoxicity in mice after administration of methamphetamine. Psychopharmacology 2014 January; 231 (1): 159-166. [Pubmed]
  27. Zhang JC, Li SX, Hashimoto K: R (-)-Ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine. Pharmacol. Biochem. Behav. 2014 January; 116: 137-141. [Pubmed]
  28. 橋本謙二: NMDA受容体拮抗薬ketamineの即効性の抗うつ作用.臨床精神薬理 2014 November; 17 (11): 1495-1500.
  29. 橋本謙二:抗炎症作用を用いた精神疾患の治療.精神科 25 (2): 153-156、2014.
  30. 橋本謙二:統合失調症のNMDA受容体仮説と新しい治療法.日本生物学的精神医学会誌 2014; 25 (2): 109-112.

2013年

  1. Albayrak Y, Hashimoto K: Beneficial effects of sigma-1 agonist fluvoxamine for tardive dyskinesia and tardive akathisia in patients with schizophrenia: report of three cases. Psychiatry Investigation 2013 December; 10: 417-420. [Pubmed]
  2. Yamamori H, Hashimoto R, Ishima T, Kishi F, Yasuda Y, Ohi K, Fujimoto M, Umeda-Yano S, Ito A, Hashimoto K, Takeda M: Plasma levels of mature brain-derived neurotrophic factor (BDNF) and matrix metalloproteinase-9 (MMP-9) in treatment-resistant schizophrenia treated with clozapine. Neurosci. Lett. 2013 Nov. 27; 556: 37-41. [Pubmed]
  3. Ünsal C, Albayrak Y, Albayrak N, Kuloğlu M, Hashimoto K: Reduced serum paraoxonase 1 (PON1) activity in patients with schizophrenia treated with olanzapine, but not quetiapine. Neuropsychiatrc Disease Treatment 2013; October; 9: 1545-1552. [Pubmed]
  4. Ermilov M, Gelfin E, Levin R, Lichtenberg P, Hashimoto K, Javitt DC, Heresco-Levy U: A pilot double-blind comparison of D-serine and high-dose olanzapine in treatment-resistant patients with schizophrenia. Schizophrenia Res. 2013; 2013 November; 150 (2-3): 604-605[Pubmed]
  5. Zhong N, Jiang H, Wu J, Chen H, Lin S, Zhao Y, Du J, Ma XC, Chen C, Gao C, Hashimoto K, Zhao M: Reliability and validity of the Chinese version of the Cogstate battery Chinese language version in schizophrenia. PLoS ONE 2013 September 2; 8 (9): e74258. [Pubmed]
  6. Takahashi M, Shirayama Y, Muneoka K, Suzuki M, Sato K, Hashimoto K: Low openness on the revised NEO personality inventory as a risk factor for treatment-resistant depression. PLoS ONE 2013; 2013 September 3; 8 (9): e71964. [Pubmed]
  7. *Ma M, *Ren Q, Fujita Y, Ishima T, Zhang JC, Hashimoto K: Effects of AS2586114, soluble epoxide hydrolase inhibitor, on hyperlocomotion and prepulse inhibition deficits in mice after administration of phencyclidine. Pharmacol. Biochem. Behav. 2012 September; 110: 98-103. (*equal contribution)[Pubmed]
  8. Takahashi M, Shirayama Y, Muneoka K, Suzuki M, Sato K, Hashimoto K: Personality traits as risk factors for treatment-resistant depression. PLoS ONE 2013 May 22; 8 (5): e63756. [PubMed]
  9. Yoshimi N, Futamura T, Hashimoto K: Prenatal immune activation and subsequent peripubertal stress as a new model of schizophrenia. Expert Rev. Neurother. 2013 July; 13 (7): 747-750. [Pubmed]
  10. Hashimoto K: Editorial: Therapeutic implications for NMDA receptors in mood disorders. Expert Rev Neurother 2013 July; 13 (7): 735-737. [PubMed]
  11. Matsuoka Y, Nishi D, Noguchi H, Kim Y, Hashimoto K: Longitudinal changes in serum brain-derived neurotrophic factor in accidient survivors with posttraumatic stress disorder. Neuropsychobiology 2013; 68: 44-50. [Pubmed]
  12. Ren Q, Zhang JC, Fujita Y, Ma M, Wu J, Hashimoto K: Effects of TrkB agonist 7,8-dihydroxyflavone on sensory gating deficits in mice after administration of methamphetamine. Pharmacol. Biochem. Behav. 2013 April 6; 106: 124-127 [Pubmed]
  13. Hagiwara H, Iyo M, Hashimoto K: Neonatal disruption of serine racemase causes schizophrenia-like behavioral abnormalities in adulthood: Clinical rescue by D-serine. PLoS One 2013 April; 8 (4): e62438. [Pubmed]
  14. Hashimoto K, Sasaki T, Ksihimoto A: Old drug ifenprodil, new hope for PTSD with a history of childhood abuse. Psychopharmacology 2013 May; 227 (2): 375-376. [Pubmed]
  15. Muneoka K, Shirayama Y, Horio M, Iyo M, Hashimoto K: Distinct states of brain amino acids in rat models presenting learned helplessness or non-leraned helplessness. Psychopharmacology 2013 September; 229 (1): 63-71. [Pubmed]
  16. Hashimoto K, Malchow B, Falkai P, Schmitt A: Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. Eur. Arch. Psychiatry Clin. Neurosci. 2013 August; 263 (5): 367-377. [PubMed]
  17. Sasaki T, Hashimoto K, Okawada K, Tone J, Machizawa A, Tano A, Nakazato M, Iyo M: Ifenprodil for the treatment of flashbacks in adolescent female posttraumatic stress disorder patients with a history of abuse. Psychother. Psychosom.2013 August; 82: 344-345. [Pubmed]
  18. Hashimoto K: Potential role of sigma-1 receptor chaperone in the beneficial effects of donepezil for dementia with Lewy bodies. Clin. Psychopharmacol. Neurosci. 2013 April; 11 (1): 43-44. [Pubmed]
  19. Kishimoto A, Hashimoto K: Reply to: Acute stress symptoms do not worsen in PTSD and abuse with a single subanesthetic dose of ketamine. Biol. Psychiatry 2013 June 15; 73 (12): e39.[PubMed]
  20. Iyo M, Tadokoro S, Kanahara N, Niitsu T, Watanabe H, Hashimoto K: Optimal extent of dopamine D2 receptor occupancy by antipsychotics for treatment of dopamine supersensitivity psychosis and late-onset psychosis. J. Clin. Psychopharmacol. 2013 June; 33 (3): 398-404. [Pubmed]
  21. Horio M, Mori H, Hashimoto K: Is D-cycloserine a prodrug for D-serine in the brain? Biol. Psychiatry 2013 June 15; 73 (12): e33-e34. [PubMed]
  22. Horio M, Fujita Y, Hashimoto K: Therapeutic effects of metabotropic glutamate receptor 5 positive allosteric modulator CDPPB on phencyclidine-induced cognitive deficits in mice. Fund. Clini. Pharmacol. 2013 October; 27: 483-488. [PubMed]
  23. Shimmura C, Suzuki K, Iwata Y, Tsuchiya KJ, Ohno K, Matsuzaki H, Iwata K, Kameno Y, Takahashi T, Wakuda T, Nakamura K, Hashimoto K, Mori N: Enzymes in the glutamate-glutamine cycle in the anterior cingulate cortex in postmortem brain of subjects with autism. Mol. Autism 2013 Mar 26; 4 (1): 6. [PubMed]
  24. *Horio M, *Ishima T, Fujita Y, Inoue R, Mori H, Hashimoto K: Decreased levels of D-aspartic acid in the forebrain of serine racemase (Srr) knock-out mice. Neurochem. Int. 2013 March 20; 62: 843-847. (*equal contribution) [Pubmed]
  25. Ma XC, Dang YH, Jia M, Ma R, Wang F, Wu J, Gao GG, Hashimoto K: Long-lasting antidepressant action of ketamine, but not glycogen synthase kinase-3 inhibitor SB216763, in the chronic mild stress model of mice. PLoS One 2013 February 4;8 (2): e56053. [PubMed]
  26. Ohgi Y, Futamura T, Kikuchi T, Hashimoto K: Effects of antidepressants on alterations in serum cytokines and depressive-like behavior in mice after lipopolysaccharide administration. Pharmacol. Biochem. Behav. 2013 February; 103 (4): 853-859. [Pubmed]
  27. Kanahara N, Sekine Y, Haraguchi T, Uchida Y, Hashimoto K, Shimizu E, Iyo M. Orbitofrontal cortex abnormality and deficit schizophrenia. Schizophrenia Res. 2013 Feb; 143 (2-3): 246-252. [PubMed]
  28. Matsuoka Y, Nishi D, Yonemoto N, Hamazaki K, Matsumura K, Noguchi H, Hashimoto K, Hamazaki T: Tachikawa Project for Prevention of Posttraumatic Stress Disorder with Polyunsaturated Fatty Acid (TPOP): Study protocol for a randomized controlled trial. BMC Psychiatry2013 Jan 5;13 (1): 8. [Pumed]
  29. Kishimoto A, Yatomi K, Yokoyama Y, Nakatsu N, Fujita K, Hashimoto K: Ifenprodil for emotional incontinence in patients with vascular dementia: two case reports. J. Clin. Psychopharmacol. 2013 February; 33 (1): 143-145. [PubMed]
  30. Hashimoto K: Editorial: Understanding depression: linking brain-derived neurotrophic factor (BDNF), transglutaminase 2 (TG2), and serotonin. Expert Rev. Neurother. 2013 January; 13 (1): 5-7. [Pubmed]
  31. Hashimoto K: Sigma-1 receptor chaperone and brain-derived neurotrophic factor: emerging links between cardiovascular disease and depression. Prog. Neurobiol. 2013 January; 100: 15-29. [Pubmed]
  32. 橋本謙二:うつ病の病態におけるBDNF-TrkB受容体シグナル系の役割.医学のあゆみ 2013年2月号; 244 (5): 471-475.
  33. 橋本謙二、石間 環、藤田有子、張 琳:抗生物質ミノサイクリン:覚せい剤・麻薬関連障害に対する治療薬としての可能性. 日本アルコール・薬物医学会雑誌 2013年 48 (2): 118-125.
  34. 石間 環、伊豫雅臣、橋本謙二:アリピプラゾールの神経突起促進作用に関する研究.日本神経精神薬理学雑誌 2013年 33: 59-60.
  35. 橋本謙二.統合失調症のNMDA受容体機能低下仮説に基づいた新規治療薬の開発状況. 臨床精神医学 2013年7月、42 (7): 927-934.
  36. 橋本謙二.うつ病の病態におけるグルタミン酸神経系の役割と新規治療薬の開発.日本生物学的精神医学会誌 2013年9月; 24 (3): 153-156.

2012年

  1. Albayrak Y, Hashimoto K: Beneficial effects of sigma-1 agonist fluvoxamine for tardive dyskinesia in patients with post-psychotic depression: report of five cases. Prim. Care Companion CNS Disorders 2012 Dec; 14 (6).
  2. Harai T, Inoue R, Fujita Y, Tanaka A, Horio M, Hashimoto K, Hongou K, Miyawaki T, Mori H: Decreased susceptibility to seizures induced by pentylenetetrazole in serine racemase knockout mice. Epilepsy Res. 2012 Dec.; 102 (3): 180-187. [PubMed]
  3. Berry J, Ferraris DV, Duvall B, Hin B, Rais R, Alt J, Thomas AG, Rojas C, Hashimoto K, Slusher BS, Tsukamoto T: Synthesis and SAR of 1-hydroxy-1H-benzo[d]imidazole-2(3H)-ones as inhibitors of D-amino acid oxidase. ACS Med. Chem. Lett.2012 October 11; 3 (10): 839-843. [PubMed]
  4. Ishima T, Iyo M, Hashimoto K: Neurite outgrowth mediated by the heat shock protein HSP90α: a novel target for the antipsychotic drug aripiprazole. Transl. Psychiatry 2012 October 16; 2: e170. [PubMed]
  5. Yoshida T, Ishikawa M, Niitsu T, Nakazato M, Watanabe H, Shiraishi T, Shiina A, Hashimoto T, Kanahara N, Hasegawa T, Enohara M, Kimura H, Iyo M, Hashimoto K: Decreased serum levels of mature brain-derived neurotrophic factor (BDNF), but not its precursor proBDNF, in patients with major depressive disorder. PLoS One 2012 August 3; 7 (8): e42676. [PubMed]
  6. Nakazato M, Arakawa S, Takase M, Suzuki M, Shiina A, Hashimoto T, Kanahara N, Kimura H, Niitsu T, Yoshida T, Shiraishi T, Watanabe H, Ishima T, Fujita Y, Hashimoto K, Shimizu E, Iyo M: Effectiveness of enteral formula with enriched polyunsaturated fatty acids in the treatment of anorexia nervosa: a pilot open case study. Open Nutrition J. 2012; 6, 104-107.
  7. Shirai Y, Fujita Y, Hashimoto K. Effects of the antioxidant sulforaphane on hyperlocomotion and prepulse inhibition deficits in mice after administration of phencyclidine. Clin. Psychopharmacol. Neurosci. 2012 August;10 (2): 94-98. [PDF]
  8. Wang W, Fu W, Wu J, Ma XC, Sun XL, Huang Y, Hashimoto K, Gao GG: Prevalence of PTSD and depression among the junior middle school students in a rural town far from the epicenter of the Wenchuan earthquake in China. PLoS ONE 2012 July 23; 7 (7): e41665. [Pubmed]
  9. Gong N, Wang YC, Wang HL, Ma AN, Hashimoto K, Wang YX: Interactions of the potent D-amino acid oxidase inhibitor CBIO with morphine in pain and tolerance to analgesia. Neuropharmacology 2012 September; 63 (3): 460-468. [PubMed]
  10. Niitsu T, Fujisaki M, Shiina A, Yoshida T, Hasegawa T, Kanahara N, Hashimoto T, Shiraishi T, Fukami G, Nakazato M, Shirayama Y, Hashimoto K, Iyo M: A randomized, double-blind, placebo-controlled trial of fluvoxamine in patients with schizophrenia: a preliminary study. J. Clin. Psychopharmacol. 2012 October; 32: 593-601. [PubMed]
  11. Hashimoto K, Furuse, T: Sigma-1 receptor agonist fluvoxamine for delirium in elderly adults. Int. J. Geriatr. Psychiatry 2012 September; 27: 981-983. [PubMed]
  12. Tadokoro S, Okamura N, Sekine Y, Kanahara N, Hashimoto K, Iyo M: Chronic treatment with aripiprazole, a dopamine D2 receptor partial agonist, stabilizes dopamine sensitivity in rats. Schizophrenia Bull. 2012 Sept; 38 (5): 1012-1020. [PubMed]
  13. Chen H, Wu J, Zhang J, Fujita Y, Ishima T, Iyo M, Hashimoto K: Protective effects of antioxidant sulforaphane on the behavioral changes and neurotoxicity in mice after administration of methamphetamine. Psychopharmacology 2012 July; 222 (1): 37-45. [PubMed]
  14. Tokita K, Fujita Y, Yamaji T, Hashimoto K: Depressive-like behavior in adrenocorticotropic hormone-treated rats by blocked by memantine. Pharmacol. Biochem. Behav. 2012 May 17; 102 (2): 329-334. [PubMed]
  15. Ishima T, Hashimoto K: Potentiation of nerve growth factor-induced neurite outgrowth in PC12 cells by ifenprodil: role of sigma-1 receptor and IP3 receptor. PLoS One 2012 May 24; 7 (5): e37989. [PubMed]
  16. Hashimoto K: A BDNF Val66Met polymorphism and ketamine-induced rapid antidepressant action. Clin. Psychopharmacol. Neurosci. 2012 April; 10 (1): 59-60. [PDF]
  17. Zhang J, Toyohara J, Wu J, Ishiwata K, Hashimoto, K: In vivo evaluation of three radioligands for glycine transporter 1 in the mouse brain. Clin. Psychopharmacol. Neurosci.2012 April; 10 (1): 44-48. [PDF]
  18. Nakazato M, Hashimoto K, Shimizu E, Niitsu T, Iyo M: Possible involvement of brain-derived neurotrophic factor (BDNF) in eating disorders (ED). IUBMB Life 2012; May; 64 (5): 355-361. [PubMed]
  19. Yoshida T, Iyo M, Hashimoto K: Recent advances in the potential therapeutic drugs for cognitive deficits in schizophrenia. Curr. Psychiatry Rev.2012 May; 8 (2): 140-150.
  20. Horio M, Kohno M, Fujita Y, Ishima T, Inoue R, Mori H, Hashimoto K. Role of serine racemase in behavioral sensitization in mice after repeated administration of methamphetamine. PLoS One 2012 April 18; 7 (4): e35494. [PubMed]
  21. Yoshida T, Ishikawa M, Iyo M, Hashimoto K. Serum levels of mature brain-derived neurotrophic factor (BDNF) and its precursor proBDNF in healthy subjects. Open Clin. Chem. J. 2012 April; 5: 7-12. [PDF]
  22. Fujita Y, Kunitachi S, Iyo M, Hashimoto K: Antibiotic drug minocycline prevents methamphetamine-rewarding effects in mice. Pharmacol. Biochem. Behav. 2012 April; 101 (2): 303-306. [PubMed]
  23. Niitsu T, Iyo M, Hashimoto K: Sigma-1 receptor agonists as therapeutic drugs for cognitive impairments in neuropsychiatric disease. Curr. Pharm. Des. 2012; March; 18 (7): 875-883. [PubMed]
  24. Kishimoto A, Kaneko M, Gotoh T, Hashimoto K: Ifenprodil for the treatment of flashbacks in female Posttraumatic Stress Disorder patients with a history of childhood sexual abuse. Biol. Psychiatry 2012 February 15; 71 (4): e7-e8. [PubMed]
  25. Tokita K, Yamaji T, Hashimoto K: Roles of glutamate signaling in preclinical and/or mechanistic models of depression. Pharmacol Biochem Behav 2012 February; 100 (4): 688-704. [PubMed]
  26. Arakawa S, Shirayama Y, Fujita Y, Ishima T, Horio M, Muneoka K, Iyo M, Hashimoto K: Minocycline produced antidepressant-like effects on the learned helplessness rats with alterations in levels of monoamine in the amygdala and no changes in BDNF levels in the hippocampus at baseline. Pharmacol. Biochem. Behav. 2012 Jan; 100 (3): 601-606. [PubMed]
  27. 橋本謙二:統合失調症の認知機能障害改善薬の最新知見.Schizophrenia Frontier 2012年10月; 13 (1): 7-10.
  28. 橋本謙二:高齢者とグルタミン酸機能.老年精神医学雑誌 2003年8月; 23 (8): 932-937.
  29. 橋本謙二:統合失調症の病態からみた新しい治療薬.日本生物学的精神医学会誌 2012年6月; 23 (2): 97-101.
  30. 橋本謙二:精神疾患の血液バイオマーカーとしてのBDNFの臨床検査への応用可能性.臨床精神医学 2012年7月; 41 (7): 879-884.
  31. 橋本謙二:精神疾患の病態解析に基づいた新しい治療薬の創製.月刊ファインケミカル 2012年7月; 41 (7): 11-14.
  32. 橋本謙二(2012)統合失調症における内在性D-セリンと新規治療戦略. 臨床精神薬理2012年5月; 15 (5): 665-669.
  33. 橋本謙二:精神神経疾患の新規治療薬としての抗生物質ミノサイクリン.分子精神医学 2012年1月; 12 (1), 15-20.

2011年

  1. Ishikawa M, Sakata M, Toyohara J, Oda K, Ishii K, Wu J, Yoshida Y, Iyo M, Ishiwata K, Hashimoto K: Occupancy of alpha 7 nicotinic acetylcholine receptors in the brain by tropisetron: A PET study using [11C]CHIBA-1001 in healthy human subjects. Clin. Psychopharmacol. Neurosci. 2011; Dec; 9 (3): 111-116.[PDF]
  2. Niitsu T, Shirayama Y, Matsuzawa D, Hasegawa T, Shiina A, Hashimoto T, Kanahara N, Shiraishi T, Fukami G, Fujisaki M, Watanabe H, Nakazato M, Asano M, Kimura S, Hashimoto K, Iyo M: Associations of serum brain-derived neurotrophic factor with cognitive impairments and negative symptoms in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011l2011 Dec 1; 35 (8): 1836-1840. [PubMed]
  3. Shinmura C, Suda S, Tsuchiya KJ, Hashimoto K, Ohno K, Matsuzaki H, Iwata K, Matsumoto K, Wakuda T, Kameno Y, Suzuki K, Tsujii M, Nakamura K, Takei N, Mori N: Alteration of plasma glutamate and glutamine levels in children with high-functioning autism. PLoS ONE 2011 October; 6 (10): e25340. [PubMed]
  4. Kobayakawa M, Inagaki M, Fujimori M, Hamazaki K, Hamazaki T, Akechi T, Tsugane S, Nishiwaki Y, Goto K, Hashimoto K, Yamawaki S, Uchitomi Y: Serum brain-derived neurotrophic factor and antidepressant-naive major depression after lung cancer diagonosis. Jap. J. Clin. Oncol. 2011 Oct; 41 (10): 1233-1237. [PubMed]
  5. Tadokoro S, Kanahara N, Kikuchi S, Hashimoto K, Iyo M: Fluvoxamine prevents onseto of psychosis: a case report of a patient at ultra-high risk of psychotic disorder. Ann. Gen. Psychiatry 2011 Sep 30; 10 (1): 26. [PubMed]
  6. Sasaki T, Niitsu T, Hashimoto T, Kanahara N, Shiina A, Hasegawa T, Kimura H, Ishikawa M, Tone J, Yamauchi A, Hosoda Y, Kunou M, Takahashi J, Ishima T, Fujita Y, Nakazato M, Hashimoto K, Iyo M: Decreased levels of brain-derived neurotrophic factor in male pediatric patients with depression. Open Clin. Chem. J. 2011 September 30; 4: 28-33.[PDF]
  7. Shirayama Y, Muneoka K, Fukumoto M, Tadokoro S, Hashimoto K, Iyo M: Infusions of allopregnanolone into the hippocampus and amygdala, but not into nucleus accumbens and medial prefrontal cortex, produce antidepressant effects on the learned helplessness rats. Hippocampus 2011 Oct; 21 (10): 1105-1113.[PubMed]
  8. Horio M, Kohno M, Fujita Y, Ishima T, Inoue R, Mori H, Hashimoto K: Levels of D-serine in the brain and peripheral organs of serine racemase (Srr) knock-out mice. Neurochem. Int. 2011 November; 59: 853-859.
  9. Shirayama Y, Konishi T, Hashimoto K: Effects of add-on cilostazol on cognition in patients with schizophrenia: an open-label pilot trial J. Clin. Psychopharmacol. 2011 Oct. 1; 31 (5): 659-661. [PubMed]
  10. Matsuzawa D, Hashimoto K: MRS study of antioxidant defense system in schizophrenia. Antioxi. Redox Sig. 2011 Oct 1; 15 (7): 2057-2065. [PubMed]
  11. Hashimoto K: The role of glutamate on the action of antidepressants. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011 August 15; 35 (7): 1558-1568.[PubMed]
  12. Matsuoka Y, Nishi D, Yonemoto N, Hamazaki K, Hamazaki T, Hashimoto K: Potential role of BDNF in omega-3 fatty acid supplementation to prevent posttraumatic distress after accidental injury: An open-labeled pilot study. Psychother. Psychosom. 2011 June 30; 80 (5): 310-312.[PubMed]
  13. Zhang J, Wu J, Toyohara J, Fujita Y, Chen H, Hashimoto K. Pharmacological characterization of [3H]CHIBA-3007 binding to glycine transporter 1 in the rat brain. PLoS ONE 2011; 2011 June 23; 6 (6): e21322. [PubMed]
  14. Ma XC, Jiang D, Jiang WH, Wang F, Jia M, Wu J, Hashimoto K, Dang JH, Gao CG: Social isolation-induced aggression potentiates anxiety and depressive-like behaviors in male mice subjected to unpredictable chronic mild stress. PLoS One 2011 Jun 17; 6 (6): e20955. [PubMed]
  15. Yoshida T, Suga M, Arima K, Muranaka Y, Tanaka T, Eguchi S, Lin C, Yoshida S, Ishikawa M, Higuchi Y, Seo T, Ueoka Y, Tomotake M, Keneda Y, Darby D, Maruff P, Iyo M, Kasai K, Higuchi T, Sumiyoshi T, Ohmori T, Takahashi K, Hashimoto K: Criterion and constract validity of the Cogstate Schizophrenia Battery in Japanese patients with schizophrenia. PLoS ONE 2011 May 26; 6 (5), e20469.[PubMed]
  16. Toyohara J, Ishiwata K, Sakata M, Wu J, Nishiyama S, Tsukada H, Hashimoto K: In vivo evaluation of cabon-11 labelled non-sarcosine-based glycine transporter 1 inhibitors in mice and conscious monkeys. Nuc. Med. Biol. 2011 May; 38 (4): 517-527. [PubMed]
  17. Hashimoto K: Can minocycline prevent the onset of Alzheimer’s disease? Ann. Neurol. 2011; 2011 April; 69 (4): 739. [PubMed]
  18. Sakata M, Wu J, Toyohara J, Oda K, Ishikawa M, Ishii K, Hashimoto K, Ishiwata K: Biodistribution and radiation dosimetry of the alpha 7 nicotinic acetylcholine receptor ligand [11C]CHIBA-1001 in human. Nuc. Med. Biol. 2011 April; 38 (3): 443-448. [PubMed]
  19. Zhang L, Yokoi F, Jin YH, DeAndrade MP, Hashimoto K, Standaert DG, Li Y: Altered dendritic morphology of Purkinje cells in Dyt1 △GAG knock-in and Purkinje-cell specific Dyt1 conditional knockout mice. PLoS ONE 2011 March 29; 6(3): e18357.[PubMed]
  20. Ishikawa M, Hashimoto K: Alpha-7 nicotinic receptor: a potential therapeutic target for schizophrenia. Curr. Pharm. Des. 2011 March; 17 (2): 121-129. [PubMed]
  21. Hashimoto K: Glycine transportor-1: a potential therapeutic target for schizophrenia. Curr. Pharm. Des. 2011 March; 17 (2): 112-120. [PubMed]
  22. Hashimoto K: Novel potential therapeutic approaches for schizophrenia. Curr. Pharm. Des. 2011 March; 17 (2): 92-93. [PubMed]
  23. Hashimoto K, Ishima T: Neurite outgrowth mediated by translation elongation factor eEF1A1: a target for antiplatelet agent cilostazol. PLoS ONE 2011 March 1; 6 (3): e17431.[PubMed]
  24. Itoh K, Ishima T, Kehler J, Hashimoto K: Potentiation of NGF-induced neurite outgrowth in PC12 cells by papaverine: role played by PLC-gamma and IP3 receptors. Brain Res. 2011; March 4; 1377: 32-40.[PubMed]
  25. Ozeki Y, Pickard BS, Kano SI, Malloy MP, Zeledon M, Sun DQ, Fujii K, Wakui K, Shirayama Y, Fukushima Y, Kunugi H, Hashimoto K, Muir WJ, Blackwood DH, Sawa A: A novel balanced chromosomal translocation found in subjects with schizophrenia and schizotypical personality disorder: altered L-serine level associated with disruption of PSAT1 gene expression. Neurosci. Res. 2011 Feb; 69 (2): 154-160. [PubMed]
  26. Takatsu Y, Fujita Y, Tsukamoto T, Slusher B, Hashimoto K: Orally active glutamate carboxypeptidase II inhibitor 2-MPPA attenuates dizocilpine-induced prepulse inhibition deficits. Brain Res. 2011 Jan; 1371: 82-86. [PubMed]
  27. Sofuoglu M, Mooney M, Kosten TR, Walters A, Hashimoto K: Minocycline attenuates subjective-rewarding effects of dextroamphetamine in humans. Psychopharmacol. 2011 Jan 31; 213 (1): 61-68. [PubMed]
  28. Hashimoto K: Role of mTOR signaling pathway in the rapid antidepressant action of ketamine. Exp. Rev. Neurotherapeu. 2011 Jan; 11 (1): 33-36. [PubMed]
  29. Gong N, Gao ZY, Huang JL, Wang YC, Hashimoto K, Wang YX: A series of DAO inhibitors specifically prevents and reverses formalin-induced tonic pain in rats. J. Pharmacol. Exp. Ther. 2011 Jan; 336 (1): 282-293. [PubMed]
  30. Zhang L, Haraguchi S, Koda T, Hashimoto K, Nakagawara A: Muscle atrophy and motor neuron degeneration in human NEDL1 transgenic mice. J. Biomed. Biotech. 2011; 2011: 831092. [PubMed]
  31. 橋本謙二(2011)特集 統合失調症の社会復帰*QOLの向上を目指したバイオ・ソーシャルな取り組み.統合失調症の病態からみた新しい治療薬の開発. 精神神経学雑誌. 113 (4): 368-372.
  32. 吉田泰介、伊豫雅臣、橋本謙二(2011)薬物療法による予後改善:認知改善薬を中心に. 精神医学 53: 127-134.
  33. 谷渕由布子、伊豫雅臣、橋本謙二(2011)薬物依存症の末梢血バイオマーカーに関する最新知見:神経栄養因子およびサイトカインを中心に. 日本アルコール・薬物医学会雑誌 45: 515-524.
  34. 橋本謙二、平田幸一、加藤忠史(2011)うつ病関連疾患(PSD, 双極性障害)をめぐる最近の話題*シグマ-1受容体アゴニストの可能性を探る.臨床精神薬理 14: 303-318.
  35. 橋本謙二、岸本 朗、白山幸彦、古瀬 勉(2011)精神病性うつ病に対するシグマ-1受容体アゴニストフルボキサミン単剤治療の可能性.新薬と臨床 60: 34-43.
  36. 橋本謙二(2011)統合失調症治療薬の新たな開発の動向. 医薬ジャーナル 47: 111-115.
  37. 橋本謙二(2011)うつ・上安障害治療フォーラム.講演1:Fluvoxamineの特徴*シグマ-1受容体アゴニスト作用*. 臨床精神薬理 14: 129-140.